Neurofibromatosis type 1 is a tumor-predisposing genetic disorder. Plexiform neurofibromas are common NF1 tumors carrying a risk of malignant transformation, which is typically fatal. Little is known about mechanisms mediating initiation and identity of specific cell type that gives rise to neurofibromas. Using cell-lineage tracing, we identify a population of GAP43 + PLP + precursors in embryonic nerve roots as the cells of origin for these tumors and report a non-germline neurofibroma model for preclinical drug screening to identify effective therapies. The identity of the tumor cell of origin and facility for isolation and expansion provides fertile ground for continued analysis to define factors critical for neurofibromagenesis. It also provides unique approaches to develop therapies to prevent neurofibroma formation in NF1 patients.
INTRODUCTION
The tumor predisposition disorder Neurofibromatosis type I (NF1) is among the most common human genetic diseases and is caused by mutation in the NF1 tumor suppressor gene, which encodes a GTPase Activating Protein (GAP) that negatively regulates p21-RAS signaling (Ballester et al., 1990; Xu et al., 1990) . NF1 patients have defects in neural crest-derived tissues, leading to a wide spectrum of clinical presentations, including developmental, pigment or neoplastic aberrations of the skin, nervous system, bones, endocrine organs, blood vessels, and the eyes (Cichowski and Jacks, 2001; Ward and Gutmann, 2005; Zhu et al., 2001) . While NF1 patients are predisposed to developing multiple tumor types (Cichowski et al., 1999; Jett and Friedman, 2010; Le and Parada, 2007; Shannon et al., 1994; Vogel et al., 1999) , the most common occurring are neurofibromas. Neurofibromas are unique and complex tumors that contain proliferating Schwann-like cells and other local supporting elements of the nerve fibers, including perineurial cells, fibroblasts, and blood vessels, as well as infiltration of mast cells. Neurofibromas are classified into different subtypes. However, for clinical and prognostic implications, many clinicians simply refer to these tumors as either dermal or plexiform. Dermal neurofibromas are exclusively in the skin and occur in virtually all individuals with NF1. They initially appear at puberty and increase in number with age. Although similar to dermal neurofibromas at the cellular and ultrastructural levels, plexiform neurofibromas develop along a nerve plexus or involve multiple nerve bundles and are capable of forming large tumors. Unlike their dermal counterpart, plexiform neurofibromas are thought to be congenital and progressively enlarge throughout life. They carry a risk of malignant transformation that can metastasize widely and are often fatal. Plexiform neurofibromas can occur anywhere along peripheral nerve plexus. In fact, deep-tissue neurofibromas occur in 20%-40% of adult NF1 patients (Tonsgard et al., 1998) . The majority of internal plexiform neurofibromas manifest in the para-spinal region associated with dorsal root ganglia (DRG). Their chance of malignant transformation is much higher compared with other
Significance
In this study, we utilized a genetically engineered mouse model as a tool to identify the cell of origin for plexiform neurofibroma. Using cell-lineage tracing, we showed that the embryonic GAP43 + PLP + Schwann cell precursors originate from spinal nerve roots are the cells of origin for plexiform neurofibromas. Our studies point to the importance of stem cells and their immediate progenitors in the initiation of tumors, consistent with the notion that these neoplasms originate in a subset of primitive precursors and that most cells in an organ do not generate tumors. Identifying which cell type gives rise to a particular cancer (the cells of origin) will permit greater understanding of their pathogenesis and inform better design approaches for their treatment.
forms of plexiform neurofibromas and carries a poorer prognosis, in part because they are not evident clinically in the early stage. In addition, because of their location at the neural foramina of the vertebral column, they can impinge on the spinal cord and nerve roots, causing pain and neurological deficits. Thus, these paraspinal neurofibromas represent a serious complication of NF1.
A large body of direct and indirect studies has provided evidence that NF1 gene deletion is the requisite initial step that precedes the cascade of interactions with other cell types in the microenvironment as well as additional cell autonomous modifications for neurofibromagenesis (Joseph et al., 2008; Le et al., 2009; Wu et al., 2008; Zheng et al., 2008; Zhu et al., 2002) . Early speculation regarding the cells of origin for neurofibromas came from genetic studies examining the participation of different cell types including neural crest derivatives in the pathogenesis of many of the clinical presentations of NF1, including neurofibroma. In human neurofibromas, Schwannlike cells with biallelic NF1 mutations are the most consistently found cell type, leading to the argument that the tumors initiate in Schwann cells or their earlier precursors. Indeed, genetic mouse models have demonstrated that Nf1 deletion in the Schwann cell lineage is the genetic bottleneck for neurofibroma development (Cichowski et al., 1999; Joseph et al., 2008; Vogel et al., 1999; Wu et al., 2008; Zheng et al., 2008; Zhu et al., 2002) .
During the development of peripheral nerves, neural crest cells generate Schwann cells in a process that parallels embryonic development. Migrating neural crest stem cells emerge from the dorsal horns of the neural tube and move through immature connective tissue before the time of nerve formation and then differentiate into Schwann cell precursors (SCPs). These SCPs then become immature Schwann cells in the developing peripheral nerves until early neonatal stages. The differentiation of immature Schwann cells to form the non-myelinating and myelinating cells of mature nerves essentially occurs postnatally (Jessen and Mirsky, 2005; Woodhoo and Sommer, 2008) . Given that the majority of plexiform neurofibromas in human are congenital and generally detected at birth or in early infancy, they must arise from the early Schwann cell lineage. Indeed, genetic mouse models have demonstrated that Nf1 deletion in the embryonic Schwann cell lineage is the genetic bottleneck for neurofibroma development (Cichowski et al., 1999; Joseph et al., 2008; Vogel et al., 1999; Wu et al., 2008; Zheng et al., 2008; Zhu et al., 2002) . However, the exact developmental stage and embryonic location of the Schwann cell lineage that initiate neurofibroma formation remain unknown. NF1 patients frequently have plexiform neurofibromas in the para-spinal region at the neural foramina associated with DRG. In addition, existing mouse models of NF1 also develop neurofibromas at the DRG regions. We wish to identify the cells of origin for these para-spinal plexiform neurofibromas. We reason that they reside in the vicinity of the embryonic DRGs or at the nearby nerve roots.
RESULTS
Loss of Nf1 in Embryonic DRG/Nerve Root Neurosphere Cells Gives Rise to Classic Plexiform Neurofibroma In Vivo Recent studies have established the value of in vitro sphere assay to identify cancer stem cells as well as neural stem/progenitor cells Williams et al., 2008) . Therefore, we examined whether Nf1-deficient embryonic DRG/nerve root neurosphere cells (DNSCs) could contain the elusive cells of origin of para-spinal neurofibromas. To obtain Nf1 À/À DNSCs, we dissected DRGs/nerve roots from E13.5 Nf1 flox/flox ; Rosa26(R26R) mouse embryos (Hall, 2006) and performed the neurosphere culture. These neurosphere cells have high selfrenewal and proliferative potential (Figures S1A-S1D available online). They were subsequently infected with adenovirus carrying the Cre recombinase (Ad-CMV-Cre) to ablate Nf1 and generate Nf1 À/À ;LacZ + DNSCs, which was verified by genomic analysis of Nf1 ( Figure 1A) .
We next implanted Nf1
;LacZ + DNSCs into the sciatic nerves where close proximity to the nerve environment could be achieved as previously established through an in vivo neurofibromagenesis assay Figure 1C ; Figure S1E ). À/À DNSCs to sciatic nerves, it is unlikely that all the embryonic DNSCs could give rise to plexiform neurofibroma. In genetic mouse models, Nf1 ablation in embryonic Schwann cell lineage (PLP, Krox20, and DHH positive cells) was sufficient to induce para-spinal plexiform neurofibromas (Le et al., 2011; Wu et al., 2008; Zhu et al., 2002) , suggesting that all or at least part of the cells of origin might be inside these PLP + , Krox20 + , and DHH + embryonic Schwann cell lineage. Therefore, we next sought to determine this subpopulation within the embryonic DNSCs that could give rise to neurofibroma.
To achieve this, we crossed Plp promoter-driven, tamoxifeninducible Cre (PlpCre-ERT) (Leone et al., 2003) Figure 2A and Table 1 ). Strikingly, we also observed spontaneous transformation into malignant peripheral nerve sheath tumors (MPNST) arising from a fraction of these sciatic plexiform neurofibromas that originated from PLP + ; Nf1 À/À DNSCs (Figures 2Ai-2Al ). This is consistent with human clinical observations that about 10% of plexiform neurofibromas undergo malignant transformation (Evans et al., 2002) . These data further indicate that the cells of origin might be within the embryonic PLP + DNSCs population.
However, since Nf1 ablation in Krox20 + and DHH + embryonic
Schwann cell lineage could also give rise to para-spinal plexiform neurofibromas, we next examined whether the cells of origin are also inside the embryonic Krox20 + or DHH + DNSCs Zhu et al., 2002) . We utilized the same strategies as above using the Krox20-Cre and Dhh-Cre transgenic mice. Unexpectedly, we found that not only the Krox20 (C) Tumor on right sciatic nerve was stained with antibody against S100b and GAP43. Blue scale bars, 500 mm. White and black scale bars, 50 mm. See also Figure S1 . Figure S2A ).
We then took advantage of another marker, LacZ, to compare the specific expression pattern of LacZ among Plp, Krox20, and Dhh Cre mice. Specifically, for embryos with genotype PlpCre-ERT;R26R-LacZ, we gave the mother mice a single dose of 4-hydroxytamoxifen, an active metabolic product of tamoxifen that can be cleared relatively quickly from serum (Robinson et al., 1991) Figure S2 .
to show up inside the nerve roots, DRGs, and trigeminal ganglion (TG) at E10.5 ( Figure 3B ). Histological analysis indicated that the LacZ + (PLP + ) cells were mainly inside the nerve roots and only few scattered LacZ + (PLP + ) cells could be seen in DRG ( Figure 3B ). From E11.5 to E13.5, more LacZ + (PLP + ) cells appear in nerve roots, DRGs, TGs, and eventually peripheral nerves ( Figure 3B ). In contrast, in the Krox20-Cre mice, the LacZ + (Krox20 + ) cells first appear in nerve roots at E11.5 and stay in nerve roots until E13.5 when some peripheral nerves started to express the LacZ (Krox20). However, there were very few LacZ + (Krox20 + ) cells inside the DRG ( Figure 3C ). Similarly, in Dhh-Cre mice, we could only observe very few LacZ + (DHH + ) cells in nerve roots after E11.5. From E12.5 to E13.5, more LacZ + (DHH + ) cells were detected only at nerve roots and some of the peripheral nerves ( Figure 3D ), which were consistent with previous findings that Dhh transcripts were expressed by SCPs both in the dorsal and ventral roots at E13 (Parmantier et al., 1999 Cancer Cell
Cells of Origin for Plexiform Neurofibroma embryonic dorsal nerve roots from the DRGs, we found that only the embryonic dorsal nerve roots could robustly give rise to neurospheres, but not the E13.5 DRGs ( Figure 3E ). However, in adult mice, we found that the DRGs can also give rise to neurospheres ( Figure S2B ). Further immunofluorescence analyses demonstrate that these embryonic nerve roots generated neurosphere cells that express neural crest markers (Nestin and P75), immature Schwann cell marker GFAP, and proliferation marker Ki-67, but not the mature Schwann cell marker S100b ( Figure 3F ). ;R26R-YFP embryos, whose mother was administered with tamoxifen at E11.5, were stained for YFP, DAPI, and lineage markers: GAP43 (a-c), Nestin (d), P75 (e), BLBP (f), bIII-tubulin (g), GFAP (h), and S100b (i). DRG, dorsal root ganglia; NR, nerve root; PN, peripheral nerve; SC, spinal cord. All scale bars, 50 mm. See also Figure S3 .
Under differentiation conditions, these neurosphere cells could differentiate into Schwann cells and neurons, but not the oligodendrocytes ( Figure 3G (Figures  4Ac-A4e) . In addition, the majority of YFP + (PLP + ) cells did not express neuronal marker bIII-tubulin (Figure 4Af ). Strikingly, every YFP + (PLP + ) cell also expressed GAP43, a Schwann cell marker that is known to first appear at the precursor stage (Figures 4Ag-4Ai) , and Sox10, a marker for neural crest origin and future Schwann cell lineage ( Figure S3A ) (Kalcheim and Rohrer, 2014) . Because these PLP + GAP43
+ cells are also P75 positive but S100b negative, they are at Schwann cell precursor stage (Jessen and Mirsky, 2005) . It is well known that cell culture in vitro may vary from that in vivo. Therefore, we also characterized these PLP + cells in E13.5 PlpCre-ERT;Nf1 flox/flox ;R26R-YFP embryos and observed that YFP + (PLP + ) cells were colocalized with GAP43 mainly at nerve roots (Figures 4Ba-4Bc ). Similar to our in vitro data, they also expressed Nestin, P75, BLBP, and Sox10 (Figures 4Bd-4Bf ; Figure S3B ). They were also colocalized with bIII-tubulin (Figure 4Bg ). However, they did not express GFAP and S100b in vivo (Figures 4Bh and 4Bi ;R26R-LacZ mouse, whose mother was administered with tamoxifen at E9.5. There is strong X-gal staining in the enlarged DRGs (star mark), enlarged intercostal nerve (arrow head), and nerve root (arrow). (B) H&E and immunohistochemical staining for GAP43 and S100b in sections from these enlarged LacZ + DRGs (star mark in A).
(C) H&E staining of the DRG and its associated enlarged intercostal nerve (EIN) in (A) (arrow head). Enlarged intercostal nerve was also stained for GAP43 and S100b. fate tracing prior to tumorigenesis. X-gal staining demonstrates that LacZ + (PLP + ) cells are mainly located in nerve roots at E10.5 when we gave 4-hydroxytamoxifen to pregnant mother mice at E9.5 ( Figure 3B ;R26R-LacZ female mice. We then administered 4-hydroxytamoxifen to pregnant mother mice for one dose at E9.5. At 7 months of age, PlpCre-ERT;Nf1 flox/À ;R26R-LacZ progenies from these crosses began to show classic signs of illness: lethargy, weight loss, and paralyzed hind limbs. We observed the presence of plexiform neurofibromas with strong positive X-gal staining in close proximity to the cervical and thoracic DRGs ( Figure 5A ). Because PlpCre-ERT mediates labeling solely at the time of tamoxifen administration at E9.5, X-gal positive staining of neurofibroma cells demonstrates unambiguously that the labeled neurofibromas were derived from E9.5 PLP + precursors in the embryonic nerve roots. Histopathological analysis of these tumors indicated that the tumors exhibited cardinal features of plexiform neurofibromas ( Figure 5B ). Strikingly, we also observed plexiform neurofibroma developed along the intercostal nerve whose associated DRG appears histologically normal ( Figure 5C ). In addition, we identified the earliest form of neurofibroma exhibiting LacZ positive staining: classic pathological characteristics of neurofibroma and expressing Schwann cell marker S100b and GAP43 at the dorsal nerve roots near the DRG ( Figure 5D ). Together, these findings point to the PLP + ;GAP43 + SCPs in the embryonic nerve roots as the cells of origin for plexiform neurofibroma.
A Robust Plexiform Neurofibroma Model for Preclinical Drug Screening
The Nf1 gene encodes for neurofibromin, a Ras GTPase activating protein (GAP), and thus negatively regulates the RAS signaling pathway (Rubin and Gutmann, 2005) . This has prompted the use of specific MAP Kinase pathway inhibitors to counteract Nf1 loss-mediated tumor development (Chang et al., 2013; Jessen et al., 2013; Staser et al., 2013) or to treat Nf1 mutant animals in the effort to restore abnormal brain development and cognitive function (Li et al., 2012; Lush et al., 2008; Wang et al., 2012) . To determine if our non-germline plexiform neurofibroma model could be used as a rapid preclinical therapeutic drug screening tool to identify effective therapies, we used a highly selective pharmacological inhibitor of MEK, PD0325901, which blocks activation and phosphorylation of ERK1/2 (Chang et al., 2013) ;R26R-LacZ-Luciferase DNSCs to sciatic nerves of nude mice to generate plexiform neurofibromas. Mice were randomly assigned to PD0325901 treatment (5 mg/kg/day, 5 day/week) or vehicle as a control group ( Figure 6A ). We also tested if the MAPK pathway is activated in our neurofibromas and found that the ERK pathway is highly activated in the tumor tissues as shown by immunohistochemistry analysis (Figure 6Ba ). We then started the treatment right after the transplantation. A striking reduction in luciferase signal was observed even after only one week of PD0325901 treatment (p < 0.01). Continued treatment of PD0325901 further inhibited the proliferation of tumor cells. After 4 weeks of PD0325901 treatment, tumor cell proliferation was almost completely blunted as demonstrated by the diminishing luciferase signal. On the other hand, the luciferase signal in vehicle treatment group increased more than 10 times after 4 weeks of treatment (Figure 6Bb ). These data suggested that the PD0325901 could effectively inhibit the proliferation of plexiform neurofibroma. . After 4 weeks of treatment, both PD0325901 and vehicle treatment group were divided into two subgroups: discontinued PD0325901 or continued PD0325901 and discontinued vehicle treatment or continued vehicle treatment subgroups for an additional 4 weeks. Tumors were then harvested for X-gal staining (c) and immunostaining for ERK1/2 and p-ERK1/2 (d). Statistics were represented as the mean ± SEM (*p < 0.05). Blue scale bars, 500 mm. All other scale bars, 50 mm. See also Figure S4 .
However, it was not clear whether the inhibition effect of PD0325901 would be sustained after stopping the PD0325901 treatment. To answer this question, we divided the PD0325901 treatment group into two subgroups: discontinued PD0325901 treatment after 4 weeks or continued PD0325901 treatment for an additional 4 weeks in another group of mice. Similar to this, we also divided the vehicle treatment group into two subgroups based on continuing or discontinuing vehicle treatment for another 4 weeks. We again used the luciferase signal as a surrogate marker for tumor growth. We observed that continued treatment of PD0325901 further blunted the proliferation of neurofibroma; however, they regained the proliferative capacity after PD0325901 withdrawal. Eight weeks after transplantation of DNSCs, we sacrificed all mice and performed X-gal staining of the sciatic nerves. Vehicle treatment groups (8 weeks or 4 weeks) developed very large LacZ + neurofibromas, 4-week PD0325901 treatment dramatically reduced the growth of neurofibromas, while 8-week PD0325901 treatment almost completely prevented the proliferation of neurofibroma (Figure 6Bc ; Figure S4 ). Consistently, ERK1/2 phosphorylation was also reduced in both PD0325901 treatment groups compared with vehicle treatment groups ( Figure 6Bd ). All of these data showed the requirement of sustained Ras/Raf/MEK/ERK signaling for neurofibroma growth and that continuous PD0325901 treatment is effective in restraining this growth. Thus, our non-germline plexiform neurofibroma model provides a powerful approach for preclinical therapeutic drug screening to identify effective therapies for human clinical trials to prevent neurofibroma formation in NF1 patients, where none exist today.
DISCUSSION
Recent progress in cancer research points to the importance of stem cells and their immediate progenitors in the initiation and maintenance of many tumors, consistent with the notion that these neoplasms originate in a subset of primitive precursor cells and that most cells in an organ do not generate tumors (Alcantara Llaguno et al., 2009; Barker et al., 2009; Bonnet and Dick, 1997; Chen et al., 2012a; Goldstein et al., 2010; Le et al., 2009; Reya et al., 2001; Tysnes, 2010) . Identifying which cell type gives rise to a particular cancer (the cells of origin) will permit greater understanding of their pathogenesis and inform better design approaches for their treating. In this study, we utilized a genetically engineered mouse model as a tool to identify the cells of origin for plexiform neurofibroma. Using cell lineage tracing, we demonstrated that the embryonic PLP + ;Nf1 À/À SCPs, which originate from spinal nerve roots, give rise to plexiform neurofibroma not only in para-spinal areas but also in distal peripheral nerve. We also report a non-germline model for plexiform neurofibroma that can be used broadly as preclinical models for therapeutic testing. A large body of direct and indirect studies has provided evidence that Nf1 gene deletion is the requisite initial step that precedes neurofibromagenesis (Joseph et al., 2008; Le et al., 2009; Wu et al., 2008; Zheng et al., 2008; Zhu et al., 2002) . Cichowski et al. (1999) addressed this issue elegantly when they generated chimeric mice by injecting LacZ + Nf1 À/À ES cells into wild-type blastocysts. These mice developed microscopic neurofibromas derived from the injected ES cells, demonstrating the requirement of Nf1 homozygosity for tumor formation (Cichowski et al., 1999) . However, the extent of chimerism in these mice occurs randomly and cannot be controlled genetically. As a result, it is difficult to establish the cells of origin for these tumors. Conditional deletion of Nf1 from embryonic neural crest stem cells (NCSCs) using Wnt-1-Cre transgenic mice leads to a transient increase in NCSC frequency and self-renewal, but the isolated NCSCs fail to form tumors upon transplantation (Joseph et al., 2008) , suggesting that early NCSC derivatives may not contain potential cells of origin for plexiform neurofibroma. This observation indicates that later NCSC derivatives give rise to plexiform neurofibromas. Consistently, ablation of Nf1 in Schwann cells using P0A-Cre; Nf1 flox/À or Dhh-Cre;Nf1 flox/flox mice, which deletes Nf1 continuously from early SCPs through mature cells, efficiently induce neurofibromas development Zheng et al., 2008) . However, the Cre recombinase transgenes used in these two studies compromise Nf1 function at the early Schwann cell stages of development (at E12.5), and the Cre recombinase activity persists through the mature Schwann cell stage. Therefore, it is not possible to identify or exclude any particular Schwann cell developmental stage as the critical one for Nf1 loss-mediated tumor development. The interpretation of the data instead rests on correlations relating to detectable appearance of abnormal cells or structures. An alternative approach that can in theory provide a more precise evaluation of the evolution of NF1-associated tumors is the application of inducible Cre/loxP technology that allows temporal and spatial ablation of NF1 function in Schwann cells. Two different studies show that acute loss of Nf1 in both embryo and adult can lead to plexiform neurofibroma formation (Le et al., 2011; Mayes et al., 2011) . The fact that Nf1 inactivation in adult mice also gives rise to neurofibroma, albeit at a much lower frequency (Le et al., 2011) , indicates that either (1) mature Schwann cells can, in rare cases, give rise to neurofibroma or (2) that rare populations of progenitor cells persist within the adult peripheral nervous system. The notion that mature Schwann cells have the capability to give rise to plexiform neurofibromas is less evident. NF1 patients rarely present with plexiform tumors for the first time as adults (Ferner, 2007) . As aforementioned, Schwann cell development and terminal differentiation into myelinating cells mostly occurs postnatally. If mature Schwann cells as a whole can give rise to neurofibromas when loss of heterozygosity (LOH) occurs in adulthood, then it would be anticipated that plexiform tumors should develop widely in PlpCre-ERT mice induced postnatally since Cre-mediated recombination remains efficient in mature Schwann cells. It is not likely that the Schwann cell lineage undergoes immature to mature transition en masse at tightly defined times from the NCSC stage, to the precursor stage, to the immature stage, and onward to more differentiated stages. Instead, gradients of cells transition and migrate over extended periods with considerable overlap between the disappearance of one population and the emergence of another. Therefore, remaining compartments of precursor Schwann cells may also persist into adulthood and retain the capacity to form plexiform neurofibromas within the peripheral nerves. Indeed, given that embryonic nerve roots associate tightly with DRGs and that the harvested DRGs almost always contaminate with nerve roots, we carefully separated out the early embryonic dorsal nerve roots from the DRGs for neurosphere culture.
Unexpectedly, we found that only the embryonic dorsal nerve roots could robustly give rise to neurosphere but not the E13.5 DRGs. However, in adult mice, we found that the DRGs can give rise to neurospheres and neurofibroma when Nf1 was ablated and implanted into the sciatic nerves (data not shown). Consistently, when we acutely labeled the PLP + precursor cells with LacZ only in nerve roots at E10.5, we also observed plexiform neurofibroma developed in the peripheral nerve distal to the DRG. All of the data suggest that at least some of the cells of origin might migrate out along the nerve roots-DRG-peripheral nerve and retain the capacity to form neurofibroma later in life.
In the conditional knockout model using (Zhu et al., 2002) , demonstrating the essential role for the heterozygous environment in the development of neurofibroma. In another mouse model, a more robust Dhh-Cre driver causes plexiform neurofibroma formation in an Nf1-wildtype background ). In the current study, the PLP + ; Nf1 À/À DNSCs could also effectively give rise to plexiform neurofibromas when transplanted into the sciatic nerves of nude mice, which also have an Nf1-wild-type background. It is important to emphasize here that under these conditions, a large group of SCPs undergoes Nf1 LOH simultaneously and can therefore vie with the wild-type environment more efficiently than when only one or a very few isolated SCPs undergo LOH. In NF1 patients that harbor germline heterozygous NF1 mutations, given the defined time of gestation and size of neural crest compartment, inactivation of the other normal NF1 in the Schwann cell lineage must be rare and stochastic, such that single cells undergo completely inactivation of NF1 in a large pool of otherwise heterozygous NF1 mutant cells. In this setting, the increased secretion of SCF or other factors from heterozygous cells, including mast cells, in the tumor microenvironment provides a permissive condition to foster tumor growth . Therefore, in the experimental setting, one possible advantage of having a large pool of precursors undergoing LOH would be a rapid and dramatic increase in cytokine and growth factor secretion that could be sufficient to elicit wild-type mast cells without the need for the hypersensitive heterozygous state of the latter. As such, in the physiologic scenario, one would envision a rare Schwann cell undergoing LOH that would normally disappear except for the response of the Nf1-heterozygous microenvironment that assists it to form a tumor. In another scenario, contribution of a multitude of cells that have undergone LOH may override the otherwise requisite contributions from other factors, such as heterozygous mast cells or other cells in the microenvironment, to induce neurofibroma development. Although the tumor microenvironment is critical for neurofibroma formation Yang et al., 2008) , intrinsic proliferative signals such as those in the MAPK pathways are equally essential. Therefore, both the tumor microenvironment and MAPK pathways have been targeted in the preclinical setting to define clinically relevant pharmacodynamic variables and evaluating duration of drug effects on individual tumor (Jessen et al., 2013; Yang et al., 2008) . The purpose of preclinical drug screening is to select the most effective and safe compound from a large library. Our non-germline model for plexiform neurofibroma enables high efficiency of tumorigenesis and has a much shorter latency. Therefore, it is a reliable and robust model for in vivo drug screening with a quantifiable and reproducible outcome measure (via bioluminescent scan) to select lead compounds for clinical assessment. In addition, the ability to isolate embryonic PLP + GAP43 + cells for ex vivo expansion and Nf1 ablation to generate classic sciatic plexiform neurofibromas allows flexible and speedy manipulation with multiple genetic tools to delineate additional pathways that are perturbed upon the loss of Nf1, which are essential for neurofibroma development.
In conclusion, the identity of the tumor cells of origin and the facility for isolation and expansion for genetic alterations provide fertile ground for continued analysis to identify additional intrinsic and extrinsic factors within the tumor microenvironment that likely play essential roles in neurofibroma genesis. It is reasonable to speculate that lessons learned from investigating the molecular interactions between the neurofibroma cells of origin and their microenvironment will provide us approaches to develop effective therapies to delay and possibly prevent neurofibroma formation in NF1 patients.
EXPERIMENTAL PROCEDURES Mice
Animal care and use were approved by the Institutional Animal Care and Use Committee at University of Texas Southwestern Medical Center. The Nf1 flox/À and Nf1 flox/flox mice have been described previously (Zhu et al., 2002) . For conditional ablation of Nf1, we used a tamoxifen-inducible Cre line, the PlpCre-ERT2 transgenic mice (Leone et al., 2003) , and two non-inducible Cre lines, Krox20-Cre and Dhh-Cre (Limpert et al., 2013; Zhu et al., 2002) . The Rosa26-YFP reporter mice were described previously ). The ROSA26-lacZ and ROSA26-Luciferase reporter mice were obtained from the Jackson Laboratories.
Tamoxifen and 4-Hydroxytamoxifen Induction
Tamoxifen (Sigma-Aldrich) and 4-hydroxytamoxifen was dissolved in a sunflower oil/ethanol mixture (9:1) at 10 mg/ml and 1 mg/ml, respectively. For embryonic induction, the pregnant mice were gavaged orally with 1 mg of tamoxifen or 0.2 mg of 4-hydroxytamoxifen at E11.5 or E9.5, respectively.
Cell Culture and Differentiation Assays
Mouse embryos were removed from anesthetized 13.5-day-old pregnant female mice. Embryos were sacrificed. The spinal cord of each embryo was removed, and DRGs/nerve roots were dissected from the vertebral column with the aid of stereomicroscope. Fine scissors was used to cut and separate the nerve roots and DRGs. DRG and/or nerve root neurosphere culture was performed as previously described Patel et al., 2014; Ratner et al., 2006) . For cell proliferation assay, the single sphere cells were seeded to a 6-well plate coated with poly-D-lysine/laminin (4.0 3 10 3 cells per well)
for monolayer culture. The cell numbers of 3 wells were counted every 24 hr for 5 days. For differentiation assays, we seeded 5.0 3 10 3 cells per well of an 8-chamber slide coated with poly-D-lysine/laminin and cultured with fresh media containing B27 + 5% fetal bovine serum for 7-14 days. Then we fixed the cells with 4% paraformaldehyde for 30 min and performed immunostaining for lineage markers.
Fluorescence-Activated Cell Sorting
We harvested YFP + and YFP À DNSCs using FACSAria instrument (BD Biosciences) equipped with a 488 nm solid-state laser.
Histology, Immunostaining, and X-Gal Staining For hematoxylin and eosin (H&E) histology analysis, tissue specimens were harvested and fixed with 10% formalin in PBS for 1 day and subsequently embedded in paraffin. Sections (5 mm thick) were stained with H&E per manufacturer's protocol (StatLab). The dilutions of primary antibodies used in immunohistochemistry and immunofluorescence studies were as follows: b III-tubulin (rabbit, 1:2000, Sigma-Aldrich), BLBP (rabbit,1:800, Millipore), CD31 (rabbit, 1:200, Abcam), BrdU (rat, 1:400, Abcam), Cleaved Caspase-3 (rabbit, 1:100, Cell Signaling Technology), DHH (rabbit,1:200, Santa Cruz Biotechnology), total ERK1/2 (rabbit,1:250, Cell Signaling Technology), phospho-ERK1/2 (rabbit,1:400, Cell Signaling Technology), GAP43 (rabbit, 1:1000, Abcam), GFAP (rabbit, 1:2000, DAKO), GFP (goat, 1:300, Rockland), Krox20 (rabbit, 1:200, Covance Research Products), Nestin (rabbit, 1:5000, Abcam), P75 (rabbit, 1:400, Millipore), PLP (rabbit, 1:800, Abcam), S100 b (rabbit, 1:5000, DAKO), Sox10 (Goat,1:400, Santa Cruz Biotechnology), and Vimentin (mouse, 1:800, Santa Cruz Biotechnology). For X-gal staining, after total body perfusion with 4% paraformaldehyde, tissues or embryos were harvested, equilibrated in 30% sucrose in PBS overnight at 4 C, and stained with X-gal at 30 C overnight. The tissues were then postfixed with 10% formalin, paraffin embedded, sectioned, and counterstained with hematoxylin.
Transplantation Experiments
Sciatic nerve implantation of DNSCs was performed as previously reported (Chen et al., 2012b) . Briefly, mice were anesthetized by intraperitoneal injection of 120 ml of a mixture of ketamine (10 mg/ml) and xylazine (1 mg/ml) solution. A skin incision was made above the femur. Using iris scissors, a pocket was created within the quadriceps muscles to expose the sciatic nerve. The 40 ml of L15 medium containing 1 3 10 6 viable DNSCs was then deposited into this pocket so that DNSCs can be in contact with the SN. The quadriceps muscles were then closed with 4-0 Vicryl suture, and the skin was closed with 5-0 prolene suture. Mice were allowed to recover from anesthesia, then subject to MEK Inhibitor treatment and bioluminescent imaging.
MEK Inhibitor Treatment
MEK inhibitor PD0325901 were kindly provided by Dr. Kevin Shannon. PD0325901 was dissolved in vehicle (0.5% hydroxypropyl methylcellulose with 0.2% Tween 80; Sigma-Aldrich) at a concentration of 1 mg/ml. The solution was administered orally at the dosage of 5 mg/kg (body weight) per mouse, once per day, for 5 days/week.
Bioluminescent Imaging
Bioluminescent imaging was performed as described previously (Chau et al., 2014) . Briefly, mice were injected with 160 ul 20 mg/ml D-Luciferin Potassium Salt (Perkin Elmer) in 0.9% sterile NaCl, and total flux was quantified using IVIS Lumina II (Caliper Life Sciences) weekly.
Statistics
All data are displayed as the mean ± SEM unless specified otherwise. A two-tailed t test and Fisher exact test were applied as appropriate to evaluate statistical significance (p < 0.05 was deemed statistically significant).
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